Skip to main content
2024 Canadian Cardiovascular Congress Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Handout
Handout
Networking
Networking
On-Demand
On-Demand
Early Career Involvement
Early Career Involvement
Back
Session Evaluation

CHFS

EDUCATION

POLICY

146 - FACILITATING SYSTEM-LEVEL CHANGE IN HEART FAILURE CARE

Thursday, October 24, 2024
2:00 PM – 3:00 PM PT
Room: 215-216
Workshop Description: Heart failure represents a significant burden to patients, their caregivers, and to society generally. It affects 1 in every 2 Canadians which underscores the urgency for better solutions.

There is also limited awareness of the magnitude of the heart failure epidemic. Despite significant treatment advancements over the last 20 years, heart failure morbidity and mortality has not declined. These treatment advancements also require broad awareness and education among patients, providers, and policy makers, and evidence-based treatment recommendations are continually updated through the CCS/CHFS National Heart Failure guidelines. For instance, the national guidelines recommend natriuretic peptide (NP) testing as a fundamental heart failure diagnostic tool. Testing results inform decision-making including referrals to specialists, administration of additional tests or medications, and lifestyle interventions. Gaps in access to this test remain across the country and must be addressed to ensure equitable access to care and optimal patient outcomes. Lack of access may explain why so many people with heart failure are misdiagnosed first with asthma or pneumonia.

There is much to learn about how to facilitate system-level change in heart failure. Unlike fields such as oncology and HIV, where advocacy has driven remarkable improvements, heart failure care lags behind. Drawing insights from these successful endeavors could offer valuable lessons to our community.

The purpose of this workshop is to describe system barriers to heart failure care and will highlight new ways of advocating for change.. The perspectives of various stakeholders will be presented including potential ideas about how there can be system change.

This session will include insights and key recommendations on how to advocate for change from an HIV specialist. This will be followed by a brief overview of the present state of heart failure care in Canada, and care provider and patient perspectives on natriuretic peptide (NP) testing and access. The session will include panel discussions and an opportunity for the audience to ask questions.

Learning Objectives:

At the end of this session participants will be able to:
  • describe and apply potential strategies to facilitate system-level change to heart failure care;
  • describe the current state of natriuretic peptide testing and barriers to access in Canada; and
  • Summarize why we need heart failure advocacy in Canada.
Disclosure(s):
Robert McKelvie, MD, PhD, FRCPC: No financial relationships to disclose
Marc Bains, BBA: Astra Zeneca: Consultant/Advisory Board (Ongoing); Bayer: Consultant/Advisory Board (Ongoing); BMS: Speaker/Honoraria (Terminated, October 1, 2023); Boehringer Ingelheim: Consultant/Advisory Board (Ongoing); Novartis: Consultant/Advisory Board (Ongoing); Novo Nordisk: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Servier: Speaker/Honoraria (Terminated, September 1, 2023)
Julio S. G Montaner: No financial relationships to disclose
Rodolfo K. Pike, RN BN MN NP: No financial relationships to disclose
Stephanie Poon, MD: Bayer: Member of speaker's bureau (Ongoing); Boehringer Ingelheim: Member of heart failure advisory board (Ongoing), previous research grant (Ongoing); GSK: Member of advisory board and speaker's bureau (Ongoing); Servier: Member of national heart failure advisory board and speaker's bureaus (Terminated, January 1, 2024)
Anique Ducharme, MD, MSc, FCCS, FACCC: Abbott medical: Co-PI EVOLVE MR trial (Ongoing), Outreach conference in advanced heart failure (Ongoing); Astra-Zeneca: Guidelines conference sponsored by AZ (Ongoing), SYMPHONY trial - earliy detection of heart failure in the community (Ongoing); BridgeBio: Attribute TTR trial (Ongoing); Canadian Heart failure Society: Past president (member of the Executive board, voluntary work) and honorarium for conferences (Ongoing); Merck: National Leader, VITOR trial (Ongoing); Novartis: Guidelines conference sponsored by Novartis (Ongoing), HF-iDOC, PARTHENON (Ongoing); NovoNordisk: Conferences/satellite symposium at HFA (Ongoing), HERMES trial - Member of the steering Committe (Ongoing)
Mena Gewarges, MD: No financial relationships to disclose